DOI: 10.1128/AAC.02095-16
Article Information
PubMed
Published By
History
- Received October 18, 2016
- Returned for modification November 25, 2016
- Accepted March 26, 2017
- Published online May 24, 2017.
Copyright & Usage
Copyright © 2017 O'Riordan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license
.
Article Versions
- Accepted Manuscript version (April 03, 2017).
- You are viewing the most recent version of this article.
Author Information
- William O'Riordana,
- Courtney Tiffanyb,
- Nicole Scangarella-Omanb,
- Caroline Perryb,
- Mohammad Hossainc,
- Teri Ashtonb and
- Etienne Dumontb
- aeStudySite, San Diego, California, USA
- bGlaxoSmithKline, Upper Providence, Pennsylvania, USA
- cGlaxoSmithKline, King of Prussia, Pennsylvania, USA
- Address correspondence to Courtney Tiffany, Courtney.A.Tiffany{at}gsk.com, or Etienne Dumont, Etienne.f.dumont{at}gsk.com.
Citation O'Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E. 2017. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 61:e02095-16. https://doi.org/10.1128/AAC.02095-16 .
